<?xml version="1.0" encoding="UTF-8"?>
<p>The FDA-approved COVID-19 drug, remdesivir, is a nucleotide analog originally developed to treat Ebola infections (caused by another single-stranded RNA virus) and recently shown to inhibit the SARS-CoV-2 RdRP.
 <sup>
  <xref ref-type="bibr" rid="ref5">5</xref>
 </sup> The FDA has issued an emergency use authorization of hydroxychloroquine and chloroquine, both of which are approved to treat malaria and various autoimmune disorders, and might function by disrupting endosome-mediated entry or egress of the virus.
 <sup>
  <xref ref-type="bibr" rid="ref6">6</xref>
 </sup> Lopinavir-ritonavir are HIV protease inhibitors that are hypothesized to inhibit SARS-CoV 3CL
 <sup>pro</sup>.
 <sup>
  <xref ref-type="bibr" rid="ref7">7</xref>
 </sup> In addition to small molecule inhibitor candidates, various clinical trials are exploring the effect of known antibody therapies on COVID-19 progression or plan to test antibodies raised against viral proteins.
 <sup>
  <xref ref-type="bibr" rid="ref1">1</xref>
 </sup>
</p>
